I. Hamilton-Craig

发表

A preprocessing tool for removing artifact from cardiac RR interval recordings using three-dimensional spatial distribution mapping.

N. Stapelberg, D. Neumann, D. Shum, 2016, Psychophysiology.

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

K. Kostner, D. Colquhoun, I. Hamilton-Craig, 2010, Vascular health and risk management.

The sensitivity of 38 heart rate variability measures to the addition of artifact in human and artificial 24‐hr cardiac recordings

David L. Neumann, David H. K. Shum, N. Stapelberg, 2018, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.

P. Clifton, P. Barter, P. Nestel, 1997, Atherosclerosis.

Managing residual risk in patients receiving statin therapy

I. Hamilton-Craig, 2010, The Medical journal of Australia.

Update on lipid management: commonly asked questions

I. Hamilton-Craig, 2012 .

At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.

K. Kostner, D. Colquhoun, I. Hamilton-Craig, 2009, Heart, lung & circulation.

Primary prevention of coronary heart disease

I. Hamilton-Craig, I. Hamilton‐Craig, Ian Hamilton-Craig, 2008 .

Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.

T. S. Chee, D. S. Kim, S. H. Lee, 2021, European journal of preventive cardiology.

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.

C. Aguilar-Salinas, G. Mensah, G. Watts, 2020, JAMA cardiology.

Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration

P. Clifton, G. Watts, K. Kostner, 2017, Journal of atherosclerosis and thrombosis.

Familial hypercholesterolaemia: a look back, a look ahead

I. Hamilton-Craig, 2005, The Medical journal of Australia.

Statins and muscle damage

I. Hamilton-Craig, I. Hamilton‐Craig, 2003 .

Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency

R. Jayasinghe, I. Hamilton-Craig, M. Yudi, 2012, Case reports in medicine.

A new model of care for familial hypercholesterolaemia: what is the role of cardiology?

P. Clifton, G. Watts, A. Tonkin, 2012, Heart, lung & circulation.

Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.

K. Kostner, D. Colquhoun, I. Hamilton-Craig, 2012, International journal of evidence-based healthcare.

Bisoprolo vs.Carvedilol: A Comparison of Clinical Efficacy and Tolerability in Congestive Cardiac Failure

L. Howes, R. Jayasinghe, J. Edwards, 2009 .

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.

G. Jerums, A. Dart, J. Best, 1997, The American journal of cardiology.

MED-PED: An Integrated Genetic Strategy for Preventing Early Deaths

S. Humphries, M. Hayden, R. Lees, 1996 .

The Heart Protection Study: implications for clinical practice

I. Hamilton-Craig, I. Hamilton‐Craig, 2002, The Medical journal of Australia.

Familial hypercholesterolaemia in Australia: new insights and developments

G. Watts, I. Hamilton-Craig, 2013, The Medical journal of Australia.

NICE guidance on familial hypercholesterolaemia: all sugar and spice?

G. Watts, D. Sullivan, I. Hamilton-Craig, 2009, Heart, lung & circulation.

Clinical features and genetic analysis of three patients with severe hypertriglyceridaemia

J. Burnett, I. Hamilton-Craig, A. Hooper, 2014, Annals of clinical biochemistry.

Me d i c i n e T o d a y PEER REVIEWED ARTICLE POINTS: 2 CPD/2 PDP

I. Hamilton-Craig, I. Hamilton‐Craig, 2008 .

After ENHANCE: the cholesterol hypothesis is alive and well

I. Hamilton-Craig, 2008, The Medical journal of Australia.

Suboptimal consideration and management of potential familial hypercholesterolaemia in patients with suspected premature coronary artery disease.

R. Jayasinghe, M. Yudi, I. Hamilton-Craig, 2012, Singapore medical journal.

A multicenter double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesteremia

G. Jerums, A. Dart, J. Best, 1997 .

Mind and heart: Heart rate variability in major depressive disorder and coronary heart disease - a review and recommendations

N. Stapelberg, D. Neumann, D. Shum, 2012, The Australian and New Zealand journal of psychiatry.

Familial hypercholesterolaemia: a model of care for Australasia.

J. Emery, P. Clifton, G. Watts, 2011, Atherosclerosis. Supplements.

Management of Dyslipidaemia in the Elderly

K. Kostner, C. Hamilton-Craig, I. Hamilton-Craig, 2020, Contemporary Cardiology.

Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia.

Andrew B. Kirke, A. Keech, H. White, 2020, Heart, lung & circulation.

Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective

Andrew B. Kirke, Clara K. Chow, A. Keech, 2021, American journal of preventive cardiology.

A profile of heart disease risk factors and their relation to parents' education, fathers' occupation and family history of heart disease in 843 South Australian families: The Adelaide Children's WHO Collaborative Study *

J. Mazumdar, I. Hamilton-Craig, R. Cockington, 1995, Journal of paediatrics and child health.

Lipid-modifying therapy in the elderly

K. Kostner, D. Colquhoun, I. Hamilton-Craig, 2015, Vascular health and risk management.

Statin‐associated myopathy

I. Hamilton-Craig, I Hamilton-Craig, I. Hamilton‐Craig, 2001, The Medical journal of Australia.

A Topographical Map of the Causal Network of Mechanisms Underlying the Relationship Between Major Depressive Disorder and Coronary Heart Disease

N. Stapelberg, D. Neumann, D. Shum, 2011, The Australian and New Zealand journal of psychiatry.

Managing myopathy in the statin-intolerant patient

I. Hamilton-Craig, I. Hamilton‐Craig, 2012 .

Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders.

E. Mannarino, A. Cantafora, S. Bertolini, 2004, Atherosclerosis.

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

G. Jerums, A. Dart, J. Best, 1997 .

Myocardial infarction from isolated coronary artery vasculitis in a young patient: a rare case.

C. Hamilton-Craig, I. Hamilton-Craig, R. Markham, 2015, International journal of cardiology.

Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.

D. Alexander, J. Guyton, K. Maki, 2015, Journal of clinical lipidology.

Secondary prevention of coronary heart disease: Risk factors must be assessed and treatment targets met to prevent patients with coronary heart disease having a further cardiovascular event

I. Hamilton-Craig, I. Hamilton‐Craig, 2009 .

Screening for familial hypercholesterolaemia. Funding is difficult to obtain but screening can be international.

B. Tomlinson, I. Hamilton-Craig, I. W. Lan, 2001, BMJ.

The impact of methodology and confounding variables on the association between major depression and coronary heart disease: Review and recommendations

N. Stapelberg, D. Neumann, D. Shum, 2013 .

A model of care for familial hypercholesterolaemia: key role for clinical biochemistry.

P. Clifton, G. Watts, N. Poplawski, 2012, The Clinical biochemist. Reviews.